Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: herpes zoster

Case Report: Lymphocytic Vasculitis of the Central Nervous System

Gbemisola Olayemi, MD, Evangeline Scopelitis, MD, & Jerald M. Zakem, MD  |  January 17, 2019

Vasculitis is a group of chronic inflammatory diseases in which the blood vessel is the target of an immune reaction. They can be secondary to connective tissue disease, idiopathic or due to infection, neoplasm or drugs.1 Primary angiitis of the central nervous system (PACNS) is a rare syndrome characterized by inflammatory cell infiltration and necrosis…

Filed under:ConditionsVasculitis Tagged with:central nervous system vasculitiscyclophosphamideMethylprednisolonePrimary Angiitis of the Central Nervous System

FDA Approves Rituximab Biosimilar; Plus New Safety Data for Filgotinib in RA Patients

Michele B. Kaufman, PharmD, BCGP  |  January 7, 2019

The FDA has approved Truxima (rituximab-abbs), which is biosimilar to Rituxan (rituximab), for treating adults with CD20-positive, B-cell non-Hodgkin’s lymphoma…

Filed under:Biologics/DMARDsDrug Updates Tagged with:BiosimilarsFDAfilgotinibRheumatoid Arthritis (RA)rituximabrituximab-abbsU.S. Food and Drug Administration (FDA)

Ustekinumab May Be Effective for Lupus

Lara C. Pullen, PhD  |  November 12, 2018

New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:Lupussystemic lupus erythematosus (SLE)ustekinumab

Rheumatoid Arthritis Patients on Biologics Remain At Risk of Infection

Thomas R. Collins  |  September 20, 2018

AMSTERDAM—With new therapies coming into the marketplace, researchers are working to tease out the risk of infection for rheumatoid arthritis (RA) patients. Existing data suggest the risk of infections—even fatal ones—is real. But over time, improvements have taken hold, particularly for tuberculosis, according to an infectious disease expert at EULAR: the Annual European Congress of…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:InfectionTuberculosis

Investigators Assess Infection Risk with RA Biologics

Thomas R. Collins  |  August 29, 2018

Due to a range of factors, determining the precise infection risk posed by new biologic therapies to RA patients is difficult. But progress has been made and health registries may be helpful, said Olivier Lortholary, MD, PhD, during the 2018 EULAR: Annual European Congress of Rheumatology…

Filed under:Biologics/DMARDsDrug UpdatesEULAR/OtherMeeting Reports Tagged with:biologic drugsEULARInfectionRheumatoid Arthritis (RA)

Tanezumab Promising for OA Pain; Plus, Filgotinib Investigated for Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP  |  August 15, 2018

New research shows tanezumab may be safe and effective for patients with osteoarthritis pain…

Filed under:Drug Updates Tagged with:filgotinibhipkneeKnee Osteoarthritis (OA)osteoarthritis (OA)PainPsoriatic Arthritistanezumab

Results from Belimumab Safety Study

Michele B. Kaufman, PharmD, BCGP  |  July 13, 2018

In a long-term extension study, belimumab proved safe, demonstrating low organ damage accrual in SLE patients treated for up to nine years…

Filed under:Drug Updates Tagged with:belimumaborgan damageorgan failureSLEsystemic lupus erythematosus (SLE)

FDA Approves Baricitinib for RA Patients

Michele B. Kaufman, PharmD, BCGP  |  June 25, 2018

The FDA has approved baricitinib in a 2 mg tablet dose to treat patients with moderate to severe active rheumatoid arthritis…

Filed under:Drug Updates Tagged with:baricitinibFDA approvalRheumatoid Arthritis (RA)U.S. Food and Drug Administration (FDA)

Upadacitinib Promising for RA in Phase 3 Study

Michele B. Kaufman, PharmD, BCGP  |  December 5, 2017

In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

From the Front Lines: Managing RA Comorbidities in Primary Care

Arthritis Care & Research  |  September 27, 2017

How are comorbidities for RA patients managed outside of rheumatology? A recent Canadian study developed and assessed quality measures related to preventive care and screenings for RA patients in a primary care setting, comparing RA and non-RA patients. The results: Primary care physicians often provide similar levels of care to patients with and without RA. But RA patients were less likely to receive some cancer screenings and all necessary tests to assess their cardiovascular risk…

Filed under:ConditionsRheumatoid Arthritis Tagged with:cardiovascularcomorbiditiespreventiveprimary carePrimary Care PhysicianRheumatoid Arthritis (RA)

  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 9
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences